- Home
- WFG vs AXSM Comparison
WFG vs AXSM Comparison
Compare WFG & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFG
- AXSM
- Stock Information
- Founded
- WFG 1955
- AXSM 2012
- Country
- WFG Canada
- AXSM United States
- Employees
- WFG N/A
- AXSM N/A
- Industry
- WFG
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- WFG
- AXSM Health Care
- Exchange
- WFG Nasdaq
- AXSM Nasdaq
- Market Cap
- WFG 6.0B
- AXSM 5.1B
- IPO Year
- WFG N/A
- AXSM 2015
- Fundamental
- Price
- WFG $72.77
- AXSM $104.08
- Analyst Decision
- WFG Buy
- AXSM Strong Buy
- Analyst Count
- WFG 3
- AXSM 16
- Target Price
- WFG $105.00
- AXSM $170.50
- AVG Volume (30 Days)
- WFG 221.2K
- AXSM 694.5K
- Earning Date
- WFG 07-23-2025
- AXSM 08-04-2025
- Dividend Yield
- WFG 1.75%
- AXSM N/A
- EPS Growth
- WFG N/A
- AXSM N/A
- EPS
- WFG N/A
- AXSM N/A
- Revenue
- WFG $6,006,000,000.00
- AXSM $432,157,000.00
- Revenue This Year
- WFG $1.36
- AXSM $62.84
- Revenue Next Year
- WFG $8.10
- AXSM $60.02
- P/E Ratio
- WFG $2,907.58
- AXSM N/A
- Revenue Growth
- WFG N/A
- AXSM 72.16
- 52 Week Low
- WFG $69.48
- AXSM $72.21
- 52 Week High
- WFG $102.40
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- WFG 44.23
- AXSM 47.95
- Support Level
- WFG $72.92
- AXSM $99.75
- Resistance Level
- WFG $75.08
- AXSM $106.60
- Average True Range (ATR)
- WFG 1.75
- AXSM 3.23
- MACD
- WFG -0.18
- AXSM -0.02
- Stochastic Oscillator
- WFG 9.23
- AXSM 36.79
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board producers in the world.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.